| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-09-21 | Invir.IO™ | Transgene (France) | Cancer - Oncology | ||
| 2017-09-21 | Tremfya® (guselkumab) | psoriatic arthritis | 3 | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-09-21 | Diamyd® | type 1 diabetes | 2 | Diamyd Medical (Sweden) | Autoimmune diseases - Metabolic diseases |
| 2017-09-21 | NeuroSTAT® (cyclosporine) | traumatic brain injury | 2b | Neurovive Pharmaceutical (Sweden) | Traumatology - CNS diseases |
| 2017-09-20 | PXL770 | type 2 diabetes | 1b | Poxel (France) | Metabolic diseases |
| 2017-09-20 | Intuniv® (guanfacine hydrochloride prolonged release) | attention deficit hyperactivity disorder (ADHD) | 3 | Shire (UK - USA) Shionogi (Japan) | Mental diseases - CNS diseases |
| 2017-09-20 | Trelegy Ellipta® (combination of fluticasone furoate, umeclidinium and vilanterol) | chronic obstructive pulmonary disease (COPD) | 3 | GSK (UK) Theravance, now Innoviva (USA - CA) | Respiratory diseases |
| 2017-09-19 | TG4001 in combination with avelumab | human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy | 1b-2 | Transgene (France) | Cancer - Oncology |
| 2017-09-19 | NanoFlu™ vaccine | influenza | 1-2 | Novavax (USA - MD) | Infectious diseases |
| 2017-09-18 | tesofensine | obesity | 3 | Saniona (Denmark) Medix (Mexico) | Metabolic diseases |
| 2017-09-18 | PQ Grass | grass pollen-induced allergic rhinitis | 2 | Allergy Therapeutics (UK) | Allergic diseases |
| 2017-09-18 | AUTO2 | multiple myeloma | 1-2 | Autolus (UK) | Cancer - Oncology |
| 2017-09-18 | AUTO3 | acute lymphoblastic leukaemia | 1-2 | Autolus (UK) | Cancer - Oncology |
| 2017-09-18 | AUTO3 | diffuse large B-cell lymphoma (DLBCL) | 1-2 | Autolus (UK) | Cancer - Oncology |
| 2017-09-16 | dupilumab | moderate-to-severe atopic dermatitis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Autoimmune diseases - Dermatological diseases |
| 2017-09-16 | |||||
| 2017-09-16 | Tremfya™ (guselkumab - CNTO 1959) | psoriasis | 3 | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases - Dermatological diseases |
| 2017-09-15 | Repatha™ (evolocumab) | reduction of recurrent cardiovascular events | 3 | Amgen (USA - CA) | Cardiovascular diseases - Metabolic diseases |
| 2017-09-14 | imeglimin | type 2 diabetes | 2b | Poxel (France) | Metabolic diseases |
| 2017-09-14 | baricitinib (LY3009104) | moderate-to-severe atopic dermatitis | 2 | Eli Lilly (USA - IN) Incyte Corporation (USA - DE) | Dermatological diseases - Inflammatory diseases |
